Alkermes (ALKS) Stock Forecast & Price Target

Compare

544 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

ALKS Analyst Ratings

Moderate Buy

10 Buy

5 Hold

0 Sell

Based on 15 analysts giving stock ratings to

Alkermes

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

ALKS Stock 12 Month Forecast

Average Price Target

$40.30

▲(54.11%Upside)

Based on 15 Wall Street analysts offering 12 month price targets for Alkermes in the last 3 months. The average price target is $40.30 with a high forecast of $54.00 and a low forecast of $26.13. The average price target represents a 54.11% change from the last price of $26.15.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"22":"$22","55":"$55","30.25":"$30.3","38.5":"$38.5","46.75":"$46.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":54,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$54.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40.3,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$40.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.13,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$26.13</span>\n  </div></div>","useHTML":true}}],"tickPositions":[22,30.25,38.5,46.75,55],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Jan<br/>2025","9":"Apr<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,30.904615384615386,32.82923076923077,34.753846153846155,36.67846153846154,38.60307692307693,40.527692307692305,42.45230769230769,44.37692307692308,46.30153846153846,48.22615384615385,50.15076923076923,52.07538461538462,{"y":54,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,29.85076923076923,30.72153846153846,31.592307692307692,32.463076923076926,33.33384615384615,34.20461538461538,35.075384615384614,35.94615384615385,36.816923076923075,37.6876923076923,38.558461538461536,39.42923076923077,{"y":40.3,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,28.98,28.76076923076923,28.54153846153846,28.322307692307692,28.103076923076923,27.883846153846154,27.664615384615384,27.445384615384615,27.226153846153846,27.006923076923076,26.787692307692307,26.568461538461538,26.34923076923077,{"y":26.13,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":23.4,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.39,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.45,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.83,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.47,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":29.37,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.76,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.53,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.33,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.53,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":30.58,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":31.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.98,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$54.00

Average Price Target$40.30

Lowest Price Target$26.13

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$32

Buy

22.37%

Upside

Reiterated

07/22/25

Alkermes' overall score reflects strong financial health and positive earnings call insights. However, bearish technical trends and macroeconomic concerns weigh on the score. The company's valuation remains attractive, supporting a favorable long-term outlook.

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$29.22→$42

Buy

60.61%

Upside

Reiterated

07/28/25

Alkermes (ALKS) Receives a Buy from Stifel Nicolaus

Akash TewariJefferies

Jefferies

$50→$54

Buy

106.50%

Upside

Reiterated

07/22/25

Alkermes price target raised to $54 from $50 at JefferiesAlkermes price target raised to $54 from $50 at Jefferies

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$46

Hold

75.91%

Upside

Reiterated

07/21/25

Alkermes Hold Rating: Balancing Promising NT1 Study Results with Competitive and Valuation Challenges

Ami FadiaNeedham

Needham

$45

Buy

72.08%

Upside

Reiterated

07/21/25

Alkermes' Alixorexton Shows Promising Efficacy and Safety in VIBRANCE-1 Phase 2 Study, Earning Buy RatingWe look for additional clarity at the World Sleep Congress (Sept 5 - 10) where the detailed safety and efficacy results from the VIBRANCE-1 study will be presented. Overall, we believe the stock will trade up today on the positive topline; however, we expect the stock reaction to be limited by the lack of detailed data on both efficacy and safety.

Marc GoodmanLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

07/21/25

Alkermes Drug Update: Hold Rating Amid Positive Sleep Test Results and Cataplexy Concerns

Jason GerberryBank of America Securities

Bank of America Securities

$35

Hold

33.84%

Upside

Reiterated

07/21/25

Bank of America Securities Sticks to Its Hold Rating for Alkermes (ALKS)BofA Securities analyst Jason Gerberry reiterated a Neutral rating and $35.00 price target on Alkermes (NASDAQ: ALKS).

Jessica FyeJ.P. Morgan

J.P. Morgan

$34

Hold

30.02%

Upside

Reiterated

07/17/25

J.P. Morgan Sticks to Its Hold Rating for Alkermes (ALKS)

Andrea NewkirkGoldman Sachs

Goldman Sachs

$26.13

Buy

-0.08%

Downside

Initiated

07/15/25

Alkermes: Promising Growth with Established Neuropsychological Portfolio and Emerging Orexin Agonist Opportunities

Leonid TimashevRBC Capital

RBC Capital

$40

Hold

52.96%

Upside

Reiterated

07/07/25

RBC Capital Remains a Hold on Alkermes (ALKS)

Uy EarMizuho Securities

Mizuho Securities

$40

Buy

52.96%

Upside

Reiterated

06/26/25

We ran an investor survey over the Juneteenth weekend and now publish the results that gauge investor expectations and potential ALKS price reaction to the 2 readout for ALKS 2680 in narcolepsy type 1 (NT1). Thank you to those who participated during the holiday. (1) Surveyed investors expect a placebo-adjusted MWT of at least 25 min (comparable to TAK-861), (2) ALKS stock price could appreciate 10-20% if ALKS 2680 has better efficacy and safety/tolerability than TAK-861; (3) Surveyed investors generally expect ALKS to be flat over a single case of mild and transient visual disturbance and 10-15% price decline over multiple cases; (4) Survey indicates ALKS 2680 could reach $1B in peak sales in NT1 alone.

Ashwani VermaUBS

UBS

$33→$42

Buy

60.61%

Upside

Upgraded

06/17/25

Analysts Conflicted on These Healthcare Names: Roche Holding AG (Other OTC: RHHVF) and Alkermes (NASDAQ: ALKS)

Joseph ThomeTD Cowen

TD Cowen

$38

Buy

45.32%

Upside

Reiterated

06/03/25

TD Cowen Remains a Buy on Alkermes (ALKS)

David AmsellemPiper Sandler

Piper Sandler

$38

Buy

45.32%

Upside

Reiterated

05/29/25

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

Charles DuncanCantor Fitzgerald

Cantor Fitzgerald

$43

Buy

64.44%

Upside

Reiterated

05/11/25

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$32

Buy

22.37%

Upside

Reiterated

07/22/25

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$29.22→$42

Buy

60.61%

Upside

Reiterated

07/28/25

Alkermes (ALKS) Receives a Buy from Stifel Nicolaus

Akash TewariJefferies

Jefferies

$50→$54

Buy

106.50%

Upside

Reiterated

07/22/25

Alkermes price target raised to $54 from $50 at JefferiesAlkermes price target raised to $54 from $50 at Jefferies

Douglas TsaoH.C. Wainwright

H.C. Wainwright

$46

Hold

75.91%

Upside

Reiterated

07/21/25

Alkermes Hold Rating: Balancing Promising NT1 Study Results with Competitive and Valuation Challenges

Ami FadiaNeedham

Needham

$45

Buy

72.08%

Upside

Reiterated

07/21/25

Marc GoodmanLeerink Partners

Leerink Partners

―

Hold

―

Reiterated

07/21/25

Alkermes Drug Update: Hold Rating Amid Positive Sleep Test Results and Cataplexy Concerns

Jason GerberryBank of America Securities

Bank of America Securities

$35

Hold

33.84%

Upside

Reiterated

07/21/25

Bank of America Securities Sticks to Its Hold Rating for Alkermes (ALKS)BofA Securities analyst Jason Gerberry reiterated a Neutral rating and $35.00 price target on Alkermes (NASDAQ: ALKS).

Jessica FyeJ.P. Morgan

J.P. Morgan

$34

Hold

30.02%

Upside

Reiterated

07/17/25

J.P. Morgan Sticks to Its Hold Rating for Alkermes (ALKS)

Andrea NewkirkGoldman Sachs

Goldman Sachs

$26.13

Buy

-0.08%

Downside

Initiated

07/15/25

Alkermes: Promising Growth with Established Neuropsychological Portfolio and Emerging Orexin Agonist Opportunities

Leonid TimashevRBC Capital

RBC Capital

$40

Hold

52.96%

Upside

Reiterated

07/07/25

RBC Capital Remains a Hold on Alkermes (ALKS)

Uy EarMizuho Securities

Mizuho Securities

$40

Buy

52.96%

Upside

Reiterated

06/26/25

Ashwani VermaUBS

UBS

$33→$42

Buy

60.61%

Upside

Upgraded

06/17/25

Analysts Conflicted on These Healthcare Names: Roche Holding AG (Other OTC: RHHVF) and Alkermes (NASDAQ: ALKS)

Joseph ThomeTD Cowen

TD Cowen

$38

Buy

45.32%

Upside

Reiterated

06/03/25

TD Cowen Remains a Buy on Alkermes (ALKS)

David AmsellemPiper Sandler

Piper Sandler

$38

Buy

45.32%

Upside

Reiterated

05/29/25

Piper Sandler Sticks to Their Buy Rating for Alkermes (ALKS)

Charles DuncanCantor Fitzgerald

Cantor Fitzgerald

$43

Buy

64.44%

Upside

Reiterated

05/11/25

Cantor Fitzgerald Remains a Buy on Alkermes (ALKS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Alkermes

1 Month

xxx

Success Rate

9/16 ratings generated profit

Average Return

+3.79%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 56.25% of your transactions generating a profit, with an average return of +3.79% per trade.

3 Months

xxx

Success Rate

11/16 ratings generated profit

Average Return

+5.19%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 68.75% of your transactions generating a profit, with an average return of +5.19% per trade.

1 Year

Paul MatteisStifel Nicolaus

Success Rate

10/16 ratings generated profit

Average Return

+17.26%

reiterated a buy rating 2 days ago

Copying Paul Matteis's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +17.26% per trade.

2 Years

xxx

Success Rate

10/16 ratings generated profit

Average Return

+19.48%

reiterated a xxx

rating 2 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 62.50% of your transactions generating a profit, with an average return of +19.48% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ALKS Analyst Recommendation Trends

Rating

Mar 25

Apr 25

May 25

Jun 25

Jul 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, ALKS has received 25 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. ALKS average Analyst price target in the past 3 months is 40.30.

Each month's total comprises the sum of three months' worth of ratings.

ALKS Financial Forecast

ALKS Earnings Forecast

Next quarter’s earnings estimate for ALKS is $0.45 with a range of $0.32 to $0.56. The previous quarter’s EPS was $0.67. ALKS beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 46.30% of the time in the same period. In the last calendar year ALKS has Preformed in-line its overall industry.

ALKS Sales Forecast

Next quarter’s sales forecast for ALKS is $353.76M with a range of $340.50M to $367.65M. The previous quarter’s sales results were $390.70M. ALKS beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 56.45% of the time in the same period. In the last calendar year ALKS has Preformed in-line its overall industry.

ALKS Stock Forecast FAQ

What is ALKS’s average 12-month price target, according to analysts?

Based on analyst ratings, Alkermes plc’s 12-month average price target is 40.30.

What is ALKS’s upside potential, based on the analysts’ average price target?

Alkermes plc has 54.11% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is ALKS a Buy, Sell or Hold?

Alkermes plc has a consensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 0 sell ratings.

What is Alkermes plc’s price target?

The average price target for Alkermes plc is 40.30. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $54.00 ,the lowest forecast is $26.13. The average price target represents 54.11% Increase from the current price of $26.15.

What do analysts say about Alkermes plc?

Alkermes plc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.

How can I buy shares of ALKS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Alkermes (ALKS) Stock Forecast & Price Target

ALKS Analyst Ratings

ALKS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Alkermes

ALKS Analyst Recommendation Trends

ALKS Financial Forecast

ALKS Earnings Forecast

ALKS Sales Forecast

ALKS Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts